13.10.2016, 16:03
ValiRx Intends to Continue Presenting Clinical Data
OREANDA-NEWS. ValiRx Plc, a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering, is pleased to provide an update on recent presentations.
A presentation, in the form of a poster, was given by the Company and its Principle Clinical Investigator at the prestigious European Society for Medical Oncology ("ESMO") Conference on Monday, 10 October 2016 in Copenhagen.
The presentation provided data from the Company's "First-in-human (FIH) phase I/II, dose escalation and pharmacokinetic (PK) study to show the safety and tolerability of VAL201 in patients with advanced prostate cancer and other advanced solid tumours."
The poster showed early indications of efficacy in advanced prostate cancer with no drug-related serious adverse events recorded, as was previously announced via RNS on 13 September 2016. The study continues with expansion into other tumour types. An Endometriosis trial is also being planned.
The Company also recently gave presentations to investors at the Shares Investor Evening in Edinburgh on Wednesday, 5 October 2016 and at the Proactive Investor One2One Forum in Mayfair, London on Thursday, 6 October 2016.
A video link to Dr George Morris, COO's presentation in Edinburgh is also available on the 'News/Video' section of the ValiRx's website.
All of these events were well attended.
ValiRx intends to continue presenting clinical data at various international conferences in the future and it will update the market on progress regularly.
Dr Satu Vainikka, CEO, commented:
"We are delighted with the enthusiastic reception from the international biopharma community over our progress in oncology therapeutic development in this exciting new personalized field of medicine".
"We are extremely pleased with the results of our clinical trials and of the preliminary results on endometriosis. We look forward to updating the market on developments in due course".
A presentation, in the form of a poster, was given by the Company and its Principle Clinical Investigator at the prestigious European Society for Medical Oncology ("ESMO") Conference on Monday, 10 October 2016 in Copenhagen.
The presentation provided data from the Company's "First-in-human (FIH) phase I/II, dose escalation and pharmacokinetic (PK) study to show the safety and tolerability of VAL201 in patients with advanced prostate cancer and other advanced solid tumours."
The poster showed early indications of efficacy in advanced prostate cancer with no drug-related serious adverse events recorded, as was previously announced via RNS on 13 September 2016. The study continues with expansion into other tumour types. An Endometriosis trial is also being planned.
The Company also recently gave presentations to investors at the Shares Investor Evening in Edinburgh on Wednesday, 5 October 2016 and at the Proactive Investor One2One Forum in Mayfair, London on Thursday, 6 October 2016.
A video link to Dr George Morris, COO's presentation in Edinburgh is also available on the 'News/Video' section of the ValiRx's website.
All of these events were well attended.
ValiRx intends to continue presenting clinical data at various international conferences in the future and it will update the market on progress regularly.
Dr Satu Vainikka, CEO, commented:
"We are delighted with the enthusiastic reception from the international biopharma community over our progress in oncology therapeutic development in this exciting new personalized field of medicine".
"We are extremely pleased with the results of our clinical trials and of the preliminary results on endometriosis. We look forward to updating the market on developments in due course".
Комментарии